Likewise, a study on hepatocellular carcinomas indicated that patient tumors that were highly expressive of ELOVL6 were associated with shorter durations of overall survivability, while in a mouse-model inhibition of ELOVL6 increased survivability (43). Here, ELOVL6 is linked to hepatocellular carcinoma.